This page shows the latest Myalept news and features for those working in and with pharma, biotech and healthcare.
For example, Amgen's Blincyto (blinatumomab) for a rare form of leukaemia has been priced at $178, 000 a year, while AZ's Myalept (metreleptin) for the ultra-rare metabolic disorder
Meanwhile, AZ also said it is selling Myalept (metreleptin), an approved drug for generalised lipodystrophy, to Aegerion Pharmaceuticals. ... The latter will pay $325m upfront to acquire the global rights to Myalept, subject to an existing distributor
Epanova gets green light to reduce high levels of fat in the blood
First FDA-backed treatment for rare disease lipodystrophy. AstraZeneca's Myalept has become the first approved treatment for the rare disease lipodystrophy after getting a green light from the FDA. ... Myalept will be "a much-needed treatment option for
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...